Metoprolol for the Prevention of Acute Exacerbations of COPD
New England Journal of Medicine2019Vol. 381(24), pp. 2304–2314
Citations Over TimeTop 1% of 2019 papers
Mark T. Dransfield, Helen Voelker, Surya P. Bhatt, Keith Brenner, Richard Casaburi, Côme Camus, John A. Cooper, Gerard J. Criner, Jeffrey L. Curtis, MeiLan K. Han, Umur Hatipoğlu, Erika S. Helgeson, Vipul V. Jain, Ravi Kalhan, David A. Kaminsky, Robert J. Kaner, Ken M. Kunisaki, Allison Lambert, Matthew R. Lammi, Sarah Lindberg, Barry J. Make, Fernando J. Martínez, Charlene McEvoy, Ralph J. Panos, Robert M. Reed, Paul D. Scanlon, Frank C. Sciurba, Anthony Smith, Peruvemba Sriram, William W. Stringer, Jeremy A. Weingarten, J. Michael Wells, Elizabeth Westfall, Stephen C. Lazarus, John E. Connett
Abstract
Among patients with moderate or severe COPD who did not have an established indication for beta-blocker use, the time until the first COPD exacerbation was similar in the metoprolol group and the placebo group. Hospitalization for exacerbation was more common among the patients treated with metoprolol. (Funded by the Department of Defense; BLOCK COPD ClinicalTrials.gov number, NCT02587351.).
Related Papers
- → Chronic obstructive pulmonary disease (COPD)(2003)10 cited
- → (2006)2 cited
- → Chronic obstructive pulmonary disease; COPD(2002)1 cited
- → The Relationship between Functional Impairments and Activities of Patients with Chronic Obstructive Pulmonary Disease(2004)1 cited
- → Effects of Armergometer Exercise Training among Patients with Chronic Obstructive Pulmonary Disease.(1994)